(Stroke. 1999;30:1869-1874.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Departments of Cardiological Sciences (S.K., D.W.H.) and Cardiothoracic Surgery (T.T.), St George's Hospital Medical School, and the Departments of Clinical Psychology, University of Surrey (T.M.), and Clinical Psychology, Wolfson Neuro-Rehabilitation Centre and Atkinson Morley's Hospital (T.M.), London, England.
Correspondence to Dr Shaun Kilminster, GCPU, Hascombe Ward, Royal Surrey County Hospital, Guildford Surrey GU2 5XX, UK.
| Abstract |
|---|
|
|
|---|
MethodsIn an observational comparative study in a University Hospital Cardiac Surgical Unit, S-100 protein release during and 5 hours after the onset of cardiopulmonary bypass was compared with change (from preoperative to 6 to 8 weeks postoperative) in neuropsychological tests in 130 patients undergoing the full range of cardiac surgical procedures.
ResultsNeuropsychological performance usually improved, being significantly so in 10 of 25 parameters. S-100 area under the curve (AUC) protein release correlated with age (r=0.24, P<0.008) and bypass time (r=0.17, P<0.02). S-100 Cmax correlated with bypass times (r=0.29, P<0.0001). Bypass times correlated with memory performance (Rey R5; r=-0.21, P<0.03). Less S-100 protein release was associated with better neuropsychological performance, as indexed by significant correlations with the Rey Auditory Verbal Learning memory test, descending Critical Flicker Fusion thresholds, and the Hospital Anxiety and Depression rating scales, typically around r=0.2. Multiple regression models showed that neuropsychological tests accounted for 23% of the variance associated with S-100 AUC release, after partialing out the effects of age and bypass time.
ConclusionsThe correlation between S-100 protein release and neuropsychological function supports the belief that it is a measure of brain injury, which may be useful in future studies of mechanisms and prevention.
Key Words: cardiopulmonary bypass nerve tissue protein S-100 neuropsychological tests surgery
| Introduction |
|---|
|
|
|---|
There are 2 general patterns of brain injury seen after cardiopulmonary bypass.1 Stroke is the more obvious, associated with 1 or more discrete cerebral infarcts, resulting in a range of neurological manifestations, which depend on site and size. Stroke is relatively uncommon after cardiopulmonary bypass, and its occurrence is sporadic. The second pattern is common and was demonstrated, in our earlier studies,2 3 as a deterioration in the ability to perform neuropsychological tests for 6 to 8 weeks after surgery in approximately 25% of routine coronary patients. It is a diffuse injury, not characterized by discrete infarction or focal neurological signs. In clinical practice, there may be an interplay between the 2 patterns. For example, atheroembolism6 may contribute to both patterns, whereas microembolism of air bubbles causes a more subtle evanescent and apparently transient form of brain injury.7 8
A major difficulty in studying this problem has been the establishment of sensitive and specific measures of outcome that can be used reliably and efficiently. Neuropsychological tests have been the mainstay of this research9 but have several major drawbacks. They are time consuming, taking as much as an hour to perform, and there must be a preoperative baseline so that change can be determined. Their use is therefore limited to elective, stable patients, who can cooperate with the testing process before and after operation. Particular groups, including infants, the critically ill, and those with a different language, are automatically excluded from such studies. Furthermore, the results can be obscured by learning effects on test-retest, mood state, and medication. Nevertheless, neuropsychological tests have been used in controlled randomized trials to demonstrate the benefit of the use of an arterial filter in the bypass circuit,7 the hazards of glucose in the prime,10 and the advantage of alpha-stat over pH-stat perfusion11 ; however, we are seeking subtle changes, and very large studies will be required to show further improvement.
S-100 protein release is a plausible candidate for a sensitive and specific marker for brain injury.12 13 We have shown that S-100 protein release increases commensurately with the anticipated degree of cerebral hazard,14 and a consistent relationship to routine bypass has also been shown.15 We had found that the use of an arterial filter improved performance on neuropsychological tests in a trial of 100 patients.7 This has been reevaluated with S-100 protein as a surrogate marker, and in a study of only 40 patients, there was a significant difference.16
Although it is known individually that cardiac surgery is associated with S-100 protein release and neuropsychological deficit, no one has directly graduated S-100 with neuropsychological deficit. It is the relationship between these 2 outcomes, cognitive change and S-100 protein release, which we set out to study. If S-100 release is predictive of change in performance on neuropsychological tests after bypass, it could serve as a surrogate in prospective studies of a range of strategies aimed to optimize cardiopulmonary bypass, including choice of temperature, pulsatility, pH management, and putative neuroprotective drugs.
| Subjects and Methods |
|---|
|
|
|---|
Patients were tested in a private interview room by a psychologist (S.K.). The tests included those used in over 500 patients in previous studies: Rey Auditory Verbal Learning Test (RAVLT), Digit Symbol Substitution Test (DSST), Trail-Making Test (TMT A+B), Spot the Word Test (as an index of pre-morbid IQ), Speed and Capacity of Language Processing (SCOLP), and Critical Flicker Fusion (CFF). Patients also completed the Cognitive Failures Questionnaire (CFQ), the General Health Questionnaire 28 (GHQ), and the Hospital Anxiety and Depression Rating Scale (HADS). The tests are well described and validated,2 9 and most are used routinely in clinical practice in the United Kingdom. They were administered before surgery and 8 weeks after surgery.
Biochemical Measures
Blood was taken for S-100 protein analysis at specific
time points: before bypass and at 0.5, 1, 1.5, 2, 3, and 5 hours after
going onto bypass, as guided by pilot study data.14 From
these we derived 2 measures: the area under the curve (AUC), which is
an estimate of total protein release, and the maximum plasma
concentration (Cmax). S-100 protein was measured with the commercial
Sangtec S-100(R) kit (Sangtec Medical Sweden). This is a monoclonal,
2-site immunoradiometric assay. The Sangtec assay measures the beta
subunit of the protein S-100, which is specific to Schwann and Glial
cell damage. The sample is incubated with
125I-labeled monoclonal antibody to S-100
protein. The concentration of S-100 in the sample is determined by
measuring the radioactive count rate against that of known calibration
standards.
Statistical Analysis
Plots of S-100 Cmax and AUC data versus age, bypass time, and
all neuropsychological change scores were studied for relationships.
Correlations were examined with use of the Pearson product moment
for age and bypass time and AUC release. Other more detailed
analyses of interactions between neuropsychological tests, risk
factors, and S-100 protein (stepwise multiple regression,
analysis based on z scores and ranked poorest 15%
of change scores on neuropsychological testing) were also carried
out.
| Results |
|---|
|
|
|---|
|
S-100 protein release was measured in all of these cases and is
displayed as maximum concentration (Cmax), AUC, and its logarithm (log
AUC). Table 3
shows the various correlations between protein,
age, and neuropsychology tests. Scattergrams showed these to be all
linear relationships.
|
Age correlated with AUC (r=0.24, P<0.008), Cmax (r=0.28, P=0.002), and log AUC (r=0.33, P<0.0001). Bypass time correlated with AUC (r=0.20, P<0.02), Cmax (r=0.34, P<0.0001), and log AUC (r=0.33, P<0.0001). Older patients had significantly higher protein release (AUC and Cmax). Multiple regression models showed that age and bypass time independently accounted for significant proportions of the variance associated with protein release. The proportion of variance accounted for by both age and bypass time (with n=128) was 8% for AUC, 19% for log AUC, and 15% for Cmax.
Of the 130 patients, 114 completed preoperative and postoperative neuropsychological tests. There were 6 deaths (4.6%), and 10 patients did not perform the second set of tests because of illness or refusal.
Tests of mood state (HADS) showed highly significant improvement,
with the mean anxiety score falling from 8.2 to 5.3 and depression from
4.5 to 2.5 (t test, P<0.0001). It should be
noted that all of these mean scores are below the cutoffs that would
suggest clinical abnormality of mood. There was also significant
improvement in the GHQ, from 6.1 (mildly clinically abnormal)
preoperatively to 3.6 (normal) postoperatively (P<0.0001).
Most cognitive test results improved or were unaffected by the
operation (Table 2
).
|
Investigation of changes in cognitive test scores and self report questionnaires, from before to after the operation, by Student t test revealed a significant (P<0.05) improvement in 10 of 25 variables and a deterioration in the 3 derived memory test parameters of proactive interference. Changes in 8 tests remained significant after Bonferroni correction for multiple testing. These 7 tests pertained to speed of information processing (DSST, SCOLP), mood and psychological distress (HADS, GHQ), subjective view of memory ability (CFQ), descending CFF (DESCFF) indexing sedation, and also the previously mentioned subscale test of proactive interference from the Rey Auditory Learning Test (B/1+2).
There are competing movements in the data that need to be accounted for. In short, while the majority of patients showed a global improvement in each cognitive test postoperatively, there is a subset of patients whose test results remained stable or were impaired. Taking average (mean) scores masks these 2 movements. Additionally, although there was a global improvement, as indexed by >1 test showing improvement, some patients' scores may have deteriorated on some tests and improved on others. To provide a more thorough understanding of the data, analyses relating S-100 protein release to neuropsychological function were carried out at 3 levels, and a summary of the analyses is given below.
Correlations With S-100 Protein
Pearson product moment correlations between the three S-100
protein variables or bypass time with the 28 psychological
variables produced 17 significant results (see Table 3
). The direction of the correlation was
in every case consistent with higher protein release/longer
bypass times and poorer postoperative neuropsychological scores. All
examples are were plotted to confirm linear relationships before
correlations were carried out.
Multiple Regression
This analysis included the variable for (1) all
change scores on psychology tests as independent variables and (2)
age, sex, body mass index (BMI), Parsonnet risk scores,17
and bypass time. The measures of protein release were separately
regressed upon the independent variables and subjected to stepwise
regression procedures. The dependent variable was always the
continuous measures of S-100 protein and was not dichotomized so that
logistic regression was not required. The model that accounted for the
highest proportion of variance (24%) is given below. The equation only
includes variables which made a significant contribution in
predicting S-100 protein release (multiple R=48.9). Because
bypass time was included in the models, the 2 nonbypass cases were
dropped out of the analysis. Where the model includes both
positive and negative weightings for Rey memory subtests, this is
probably due to the rebalancing of the underestimate/overestimate of
variables entered into the stepwise model first and collinearity of
the subscales. S-100
(AUC)=0.875+0.31xbypass time-0.3xR3+0.19 xCFF+0.42xRey B+0.19xTMTB-0.29xRey B1/2
Psychological factors accounted for 14.4% of the variance and bypass time for 9.5%. For Cmax, 25.6% of the variance was accounted for by the following model (multiple R=50.6). S-100 (Cmax)=-1.43+0.41xbypass time+0.19xage+0.19 xRey B-0.16xRey 4
In this case psychological factors accounted for 6% of the variance, bypass time 16.3%, and age 3.5%. Hence, after other factors were accounted for, psychological variables alone accounted for 6% to 14% of the variance.
Dichotomized Variables
A further method of regressing the data is by dichotomizing the
change score data from psychological measures. Poor scores were defined
as those in the lowest 15% of ranked scores. Poor performance
was dummy coded 1 for those in the bottom 15% and 0 for those above
this cutoff. The dependent variable was always the continuous
measure of S-100 protein. Using this method, the proportion of variance
explained by psychological tests increases to 23% for S-100 (AUC),
with bypass time contributing another 9.5%. For Cmax, the figures are
19% (psychological tests) and bypass time another 16%.
| Open Heart Versus Closed Cardiac Surgery |
|---|
|
|
|---|
Patients in the closed group were significantly heavier (81.3±12.3 versus 72.7±10.5 kg, P=0.003) and hada higher BMI than those in the open group (27.5±3.8 versus 24.2±3.1, P=0.0003). They had marginally (P=0.07) shorter bypass times (82±33.2 versus 97± 54.2 minutes, P=0.09) than the open-heart patients. These differences did not bring about any significant difference in S-100 Cmax or AUC protein release. There were no significant differences in any of the change in neuropsychology scores.
| Discussion |
|---|
|
|
|---|
There were some statistical differences between the open-heart (valves and atrial septal defect) and closed-heart groups that some readers may find interesting. The closed group were significantly heavier and had a higher BMI than the open group. They had marginally shorter bypass times than the open-heart patients. These differences did not bring about any significant difference in S-100 Cmax or AUC protein release, nor were there any significant differences in any of the changes in neuropsychology scores.
In 2 patients the surgeon performed coronary surgery without going on to bypass. One released a small amount (AUC=0.18 and Cmax=0.35) and the other no protein. The data are presented with these patients excluded, but whether they are included (on intention to treat) or excluded did not alter any findings. Of those who went on a bypass machine, 11 of 128 showed no protein release.
The improvement in the performance in some neuropsychological tests after surgery is a change from the findings of our first study.2 It has become evident in more recent studies10 that the end point in comparative studies would be failure to show improvement rather than absolute deterioration. This improvement could in part be attributable to the better feeling of psychological well-being (improvement in GHQ scores) and in mood state (lower HADS scores) found in the postoperative period in this study. It could also be an effect due to practice, increased confidence, a reduction in ß-blocker usage, or reduced fatigue. In our earlier work these effects are presumed to have been overridden by the damaging effect of bypass as practiced at that time.
The significant correlations between S-100 protein release and change in neuropsychological test performance and the fact that the relationship is stronger with the dichotomized data supports a view that protein release is related to cognitive impairment. A cautious consideration is required, however, when interpreting findings such as these: first, because at best, neuropsychological tests account for only 23% of the variance associated with S-100 (AUC) release; and second, because there is no evidence pertaining to everyday functioning; for example, deterioration or no change from before to after operation can be associated with relatively high protein release, but we do not know whether it is associated with any measurable neuropsychological disability or handicap in daily life.
Prompted to pick the most discriminating neuropsychological test post hoc, the Rey memory test would be the obvious choice. Of note, none of our patients presented a memory impairment warranting an MRI scan, and as such the cerebral consequences of our cardiac patients studied here are well protected by our standard surgical and anesthetic protocols.
We did not find any association between Parsonnet score and S-100 release. The Parsonnet is a composite score used to assess the risk of serious adverse effects or death. It includes factors such as age, gender, left ventricular function, and mitral valve involvement. Certainly, age was found to be related to S-100 release; in a multiple regression equation, this variance would already be accounted for, leaving less-unique variance to contribute to the equations. It is also the case, that our sample of patients do fair very well, with a generalized improvement in postoperative psychometric scores. In the extreme case of death, they may be more of a relationship between S-100 and Parsonnet score.
We have tried in our previous work to understand mechanisms and now know a great deal more about the role of microbubbles,8 filters to trap them,7 the importance of acid-producing substrate load,10 pH management,11 and atheroembolism.6 Further improvement in the cerebral outcomes for patients will depend on more studies that explore both mechanisms and preventive strategies. We feel sufficiently confident that S-100 protein as the outcome measure would reliably indicate which of 2 or more perfusion strategies favored preservation of the brain. Depending on the anticipated effect of the measure, our data should be usable in power calculations in the design of these studies.
| Acknowledgments |
|---|
Received February 18, 1999; revision received June 18, 1999; accepted June 18, 1999.
| References |
|---|
|
|
|---|
2. Smith PCL, Treasure T, Newman SP, Joseph P, Ell PJ, Schneidau A, Harrison MJG. Cerebral consequences of cardiopulmonary bypass. Lancet. 1986;1:823825.[Medline] [Order article via Infotrieve]
3. Treasure T, Smith PLC, Newman S, Schneidau A, Joseph PH, Ell P, Harrison MJG. Impairment of cerebral function following cardiac and other major surgery. Eur J Cardiothorac Surg. 1989;3:216221.[Abstract]
4. Aberg T, Ronqvist G, Tyden, H, Ahlund P, Bergstrom K. Release of adenylate kinase into cerebrospinal fluid during open heart surgery and its relation to post operative intellectual function. Lancet. 1982;1:11391142.[Medline] [Order article via Infotrieve]
5. Shaw PJ, Bates D, Cartlidge NEF, Heaviside D, Julian DG, Shaw DA. Early neurological complications of coronary artery bypass surgery. BMJ. 1985;291:13841387.
6. Blauth C, Cosgrove DM, Webb BW, Ratliff NB, Boylan M, Piedmonte MR, Lytle BW, Loop FD. Atheroembolism from the ascending aorta. J Thorac Cardiovasc Surg. 1992;103:11041112.[Abstract]
7. Pugsley W, Treasure T, Klinger L, Newman S, Pascalis C, Harrison M. Microemboli and cerebral impairment during cardiac surgery. Vasc Surg. 1990;24:3443.
8. Pugsley W, Klinger L, Paschalis C, Treasure T, Harrison M, Newman S. The impact of microemboli during cardiopulmonary bypass on neuropsychological functioning. Stroke. 1994;25:13931399.[Abstract]
9.
Murkin JM, Newman SP, Stump DA, Blumenthal JA.
Statement of consensus on assessment of neurobehavioural outcomes after
cardiac surgery. Ann Thorac Surg. 1995;59:12891295.
10. Griffin S, Klinger L, Newman S, Hothersall J, McLean P, Harrison M, Sturridge M, Treasure T. The effect of substrate load and blood glucose management on cerebral dysfunction following cardiopulmonary bypass. Vasc Surg. 1992;26:656664.
11. Patel RL, Turtle MRJ, Chambers DJ, Newman S, Venn GE. Hyperperfusion and cerebral dysfunction. Effect of differing acid-base management during cardiopulmonary bypass. Eur J Cardiothorac Surg. 1993;7:457464.[Abstract]
12.
Persson L, Hardemark H-G, Gustafsson J, Rundstrom
G, Mendel-Hartvig I, Esscher T, Pahlman S. S-100 protein and
neuron-specific enolase in cerebrospinal fluid and serum: markers of
cell damage in human central nervous system. Stroke. 1987;18:911918.
13. Johnsson P, Lundqvist C, Lindgren A, Ferencz I, Alling C, Stahl E. Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood. J Cardiothorac Vasc Anesth. 1995;9:694699.[Medline] [Order article via Infotrieve]
14.
Kumar P, Dhital K. Hossein-Nia M, Patel S, Holt
D, Treasure T. S-100 protein release in a range of cardiothoracic
surgical procedures. J Thorac Cardiovasc Surg. 1997;113:953954.
15. Blomquist S, Johnsson P, Luhrs C, Malmkvist G, Solem JO, Alling C, Stahl E. The appearance of S-100 protein in serum during and immediately after cardiopulmonary bypass surgery: a possible marker for cerebral injury. J Cardiothorac Vasc Anesth. 1997;11:699703.[Medline] [Order article via Infotrieve]
16. Taggart DP, Bhattacharya K, Meston N, Standing SJ, Kay JDS, Pillai R, Johnsson P, Westaby S. Serum S-100 protein concentration after cardaic surgery: a randomised trail of arterial filtration. Eur J Cardiothorac Surg.. 1997;11:645649.[Abstract]
17. Parsonnett V, Dean D, Bernstein AD. A method of uniform stratification of risk for evaluating the results of surgery in acquired adult heart disease. Circulation. 1989;79(suppl I):I-3I-12).
This article has been cited by other articles:
![]() |
T. Gerriets, N. Schwarz, G. Sammer, J. Baehr, E. Stolz, M. Kaps, W.-P. Kloevekorn, G. Bachmann, and M. Schonburg Protecting the brain from gaseous and solid micro-emboli during coronary artery bypass grafting: a randomized controlled trial Eur. Heart J., June 18, 2009; (2009) ehp178v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.C. Whitaker, A.J.E. Green, J. Stygall, M.J.G. Harrison, and S.P. Newman Evaluation of an alternative S100b assay for use in cardiac surgery: relationship with microemboli and neuropsychological outcome Perfusion, July 1, 2007; 22(4): 267 - 272. [Abstract] [PDF] |
||||
![]() |
E. Iriz, F. Kolbakir, H. Akar, B. Adam, and H. T. Keceligil Comparison of Hydroxyethyl Starch and Ringer Lactate as a Prime Solution Regarding S-100{beta} Protein Levels and Informative Cognitive Tests in Cerebral Injury Ann. Thorac. Surg., February 1, 2005; 79(2): 666 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M.A.L. Pelsers, T. Hanhoff, D. Van der Voort, B. Arts, M. Peters, R. Ponds, A. Honig, W. Rudzinski, F. Spener, J. R. de Kruijk, et al. Brain- and Heart-Type Fatty Acid-Binding Proteins in the Brain: Tissue Distribution and Clinical Utility Clin. Chem., September 1, 2004; 50(9): 1568 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Stolz, T. Gerriets, A. Kluge, W.-P. Klovekorn, M. Kaps, and G. Bachmann Diffusion-Weighted Magnetic Resonance Imaging and Neurobiochemical Markers After Aortic Valve Replacement: Implications for Future Neuroprotective Trials? Stroke, April 1, 2004; 35(4): 888 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Haddock, W. S. C. Poston, and J. E. Taylor Neurocognitive Sequelae Following Coronary Artery Bypass Graft: A Research Agenda for Behavioral Scientists Behav Modif, January 1, 2003; 27(1): 68 - 82. [Abstract] [PDF] |
||||
![]() |
P. Johnsson, M. Backstrom, C. Bergh, H. Jonsson, C. Luhrs, and C. Alling Increased S100B in blood after cardiac surgery is a powerful predictor of late mortality Ann. Thorac. Surg., January 1, 2003; 75(1): 162 - 168. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wang, X. Wu, J. Li, F. Xiao, X. Liu, and M. Meng The Effect of Lidocaine on Early Postoperative Cognitive Dysfunction After Coronary Artery Bypass Surgery Anesth. Analg., November 1, 2002; 95(5): 1134 - 1141. [Abstract] [Full Text] [PDF] |
||||
![]() |
R I. Johnson, M. A Fox, A. Grayson, M. Jackson, and B. M Fabri Should we rely on nasopharyngeal temperature during cardiopulmonary bypass? Perfusion, March 1, 2002; 17(2): 145 - 151. [Abstract] [PDF] |
||||
![]() |
S. W. Suttner, S. N. Piper, K. Lang, I. Huttner, B. Kumle, and J. Boldt Cerebral effects and blood sparing efficiency of sodium nitroprusside-induced hypotension alone and in combination with acute normovolaemic haemodilution Br. J. Anaesth., November 1, 2001; 87(5): 699 - 705. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wan and A. P. C. Yim Is Off-Pump Cardiac Surgery Better for the Brain? Chest, January 1, 2001; 119(1): 1 - 1. [Full Text] [PDF] |
||||
![]() |
M. S. Ali, M. Harmer, and R. Vaughan Serum S100 protein as a marker of cerebral damage during cardiac surgery Br. J. Anaesth., August 1, 2000; 85(2): 287 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Herrmann, A. D. Ebert, I. Galazky, M. T. Wunderlich, W. S. Kunz, and C. Huth Neurobehavioral Outcome Prediction After Cardiac Surgery : Role of Neurobiochemical Markers of Damage to Neuronal and Glial Brain Tissue Stroke, March 1, 2000; 31(3): 645 - 650. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |